共 76 条
[1]
Munoz N(1997)Epidemiology of gastric cancer and perspectives for prevention Salud Publica Mex 39 318-330
[2]
Franceschi S(2006)Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137-2150
[3]
Kamangar F(1993)Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37-41
[4]
Dores GM(1994)Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189-190
[5]
Anderson WF(1995)Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus best supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587-591
[6]
Murad AM(2009)Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study Lancet Oncol 10 1063-1069
[7]
Santiago FF(2007)S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Lancet Oncol 9 215-221
[8]
Petroianu A(2011)Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) Gastric Cancer 14 72-80
[9]
Glimelius B(2009)Cancer statistics, 2009 CA Cancer J Clin 59 225-249
[10]
Hoffman K(2011)A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models Cancer Chemother Pharmacol 68 913-921